Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study tests which sperm selection tool boosts IVF success

NCT ID NCT07240779

Disease control Sponsor: Sunrise Fertility Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study will compare two advanced sperm selection techniques—PICSI and the ZyMot device—used during ICSI (a type of IVF). The goal is to see which method leads to more pregnancies. 300 couples will take part, with women aged 20-39. The results could help fertility clinics choose the best approach for their patients.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
PICSI dish and ZyMot microfluidic device
What this could lead to
If one method proves better, it could help more couples achieve pregnancy through IVF by selecting the healthiest sperm.
What could go wrong
This is an early-stage comparison study, not a large confirmatory trial. Results may not apply to all fertility cases, and neither method may show a clear advantage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 300 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Nov 2025

An estimate. Start dates often move.

Expected to finish

Feb 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 to 39 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria:- * Age for women is between 20-39 years old. * Body mass index (BMI) between 19 kg/m and 35 kg/m * Normal Prolactin level. * No other endocrinological abnormality including thyroid disorder or diabetes. * With antimullerian hormone (AMH) at least 1.5 ng/ml, ), with normal progesterone level. * Primary or secondary infertility at least of 2 years duration. * No evidence of endometriosis. * No other medical or surgical disease. * The day of embryo freezing is the fifth day (day 5), and all patients who undergo the process of transferring frozen embryos. * The endometrium thickness is between 8-14 mm on day of transfer. * Inclusion criteria of male partner were; presence of ejaculate motile spermatozoa with total sperm number 1 million/ml at least and sperm motility 5% or more and all patient with high DNA fragmentation index above 35%. Exclusion criteria׃- * Women were older than 40 years of age or younger than 18 years old. * Women laparoscopically diagnosed to have endometriosis within the last 1 year. * Male infertility factor with immotile sperm.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Infertile patient undergoing icsi procedure are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

infertility disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Infertile patient undergoing icsi procedure

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.